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Background: Incidence and disease pattern of childhood-onset SLE is reported to differ among ethnic groups.
Methods: To describe disease pattern and 6 month follow-up in a referral based cohort of 45 Vietnamese children
with SLE. Forty-five children who were subsequently diagnosed to have systemic lupus erythematosus (f/m = 4/1)
were referred to the Ho Chi Minh City Children’s Hospital No.1 during a 12-month period in 2009.
Results: The mean age at diagnosis was 12.8 years (SD = 2.5). Thirty-seven (82%) fulfilled criteria for lupus nephritis
(LN). At diagnosis, impressively high SLEDAI and ECLAM scores were recorded (mean and SD), 23.8 (11.6) and 6
(2.3), respectively. The mean renal SLEDAI score was 8.2. The mean haemoglobin (g/dL, SD) was 8.5 (2.1). The
Coombs test was positive in 30 of 36 children (83%). The mean plasma creatinine was 0.98 (SD 1.2) and mean
Westergren sedimentation rate was 83.6 (SD 37.4). The patient age at diagnosis was positively correlated to the
SLEDAI (p = 0.034) and ECLAM (p = 0.022). At 6 month follow-up of the 45 children, 15 patients were in complete
remission, 5 were in partial remission, 6 had stable disease, 3 had relapsed, 3 had evolving disease, 2 had ongoing
resistant disease and 4 had died. Seven patients were lost to follow-up. A second renal biopsy showed an improved
ISN class in 13 of 15; in 2 cases the ISN class remained unchanged.
Conclusions: Forty-five Vietnamese children with SLE were referred to Ho Chi Minh Children’s Hospital No. 1
during a16 month period from 2008–2009. These patients had a strikingly high prevalence of Coombs positive
anaemia, a high prevalence of lupus nephritis, and very high SLEDAI and ECLAM scores at the time of diagnosis.
While there may be referral biases, our Vietnamese SLE patients appear to have severe disease upon presentation
but do reasonably well in the short-term.Background
Fifteen to twenty percent of all systemic lupus erythema-
tosus (SLE) patients have a disease onset before the age
of 16 years. Childhood onset SLE is an unusual auto-
immune disease with high risk of severe morbidity and
mortality [1]. Incidence and disease patterns do differ
among ethnic groups. It has been established that non-
Caucasians have a higher incidence than Caucasians,
and that renal disease is more frequent in non-
Caucasian SLE children. Disease activity and damage,
however, are primarily associated with major organ dis-
ease independent of the patient's ethnicity [2-4]. The* Correspondence: rh16751@rh.dk
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reproduction in any medium, provided the orobjective of the current study was to investigate disease
patterns at the time of diagnosis in a referral-based con-
secutive cohort of 45 Vietnamese children diagnosed
with SLE at Ho Chi Minh Children’s Hospital No. 1 and
to perform a 6-month follow-up with emphasis on mor-
tality and lupus nephritis (LN).
Methods
Diagnosis
Forty-five consecutive Vietnamese children with SLE
participated in this prospective registration study. All
new cases of childhood-onset SLE referred during the
period from July 2008 to November 2009 to the tertiary
Ho Chi Minh City (HMC) Children’s Hospital No. 1
were included. The children were referred either from
rural provinces, from the southern part of Vietnam, ortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Rheumatology (ACR) SLE criteria were used for the
diagnosis [5]. At the time of diagnosis, symptoms and
biochemical parameters were recorded and used for SLE
disease activity scores. These included the SLE Disease
Activity Index (SLEDAI) and European Consensus
Lupus Activity Measurement (ECLAM) [6-8].
The SLEDAI is a validated disease activity measure for
childhood onset SLE with a total score of 0 – 105. The
tool consists of 24 weighted items grouped into follow-
ing 9 domains: central nervous system (CNS), vascular,
renal, musculoskeletal, serosal, dermal, immunologic,
constitutional and hematologic. Renal disease activity
was measured by the SLEDAI renal domain items [1].
ECLAM consists of 34 items grouped into 12 domains
(9 clinical manifestations and 3 laboratory assessments)
and measures active and evolving disease activity.
ECLAM scores ranges from 0 to 10.
All the SLEDAI and ECLAM scoring was done by one
author (ND). Renal biopsies at diagnosis were done in
suspicion of severe nephritis and evaluated according to
the ISN (International Society of Nephrology) lupus
nephritis grading system by an independent pathologist
[9]. A follow-up biopsy after initial treatment was done
whenever possible.
The following clinical symptoms and parameters were
recorded: general symptoms (fatigue, pain and discom-
fort, general malaise), fever, malar rash, discoid rash,
photosensitivity, alopecia, mouth ulcerations, vasculitis,
nephritis, CNS symptoms (headache, seizures, psychosis,
visual symptoms, cranial nerve manifestations and other
possible neurological manifestations), myositis, serositis,
gastrointestinal symptoms and pulmonary symptoms.
The blood tests performed were: haemoglobin, white
blood cell count (WBC) and differential count, platelet
count, erythrocyte sedimentation rate (ESR), C-reactive
protein, serum creatinine, blood urea nitrogen, albumen, a
24-hour urinary protein excretion, red and white casts in
urine, lactate dehydrogenase, creatinine kinase, glutamic-
oxaloacetic transaminase, and thyroid parameters. Other
tests more specific for SLE were done including a Coombs
test, C3 and C4 complement levels, the antinuclear anti-
bodies (ANA), anti-DNA, and the anticardiolipin anti-
bodies IgG and IgM. The ANA and anti-DNA levels were
assessed using ELISA. Furthermore, blood pressure, heart
rate, height, and weight were recorded. The local scientific
committee approved the study.
Treatment
Induction treatment was administered according to the
local guidelines, which were as follows.
1) All cases with CNS involvement or lupus nephritis
ISN class IV or class III (with any symptoms:nephrotic syndrome, hypertension, elevated serum
creatinine concentration, renal biopsy with 40 to 50
percent of glomeruli affected and/or crescent) were
treated with:
a) Intravenous methylprednisolone (1 g/1.73 m2/day
x 3–6 days, with a maximum dose of 1 g per
treatment) and monthly intravenous
b) Intravenous cyclophosphamide (Cyc) (1 g/m2/
month; maximum single Cyc dose 0.5 g) x 6
consecutive months;
c) Oral prednisolone 1–2 mg/kg/day reduced
according to disease activity.
2) Maintenance therapy consisted of azathioprine
(1–2 mg/kg/day) and oral prednisolone. Additional
treatment with an ACE inhibitor was administered
to the majority of nephritis patients. All other cases
or cases with mild nephritis (Class I, II, mild III)
were treated with systemic steroid only.
Renal outcome measures
A renal biopsy at diagnosis was done if proteinuria
exceeded 1 g/24 hours. Biopsy at 6 month followup was
performed only in the nephritis cases treated with
cyclophosphamide.
Renal outcome measures was in accordance with the
local clinical practice classified as:
1) Complete remission (CR): If presence of normal
serum creatinine, improvement in C3 level,
proteinuria < 100 mg/m2/day or < 1+ on urinary
dipstick and/or inactive urinary sediment;
2) Partial remission (PR): If stabilization or improvement
in serum creatinine level, improvement in C3 level,
persistent reduction of proteinuria or, if in the
nephrotic range at baseline, a decrease > 50% decrease
in proteinuria and renal protein excretion <50 mg/kg/
day, if in the non-nephrotic range at baseline, a
decrease < 50% of the pre-treatment value but renal
protein excretion not more than 100 mg/m2/day, and
reduction in active urinary casts;
3) Nonresponse (NR) If deterioration of renal function
occurs exclusive of other causes, increase in
proteinuria or reduction in proteinuria but not to the
extent of CR or PR. At the 6 month follow-up CR or
PR was regarded as favourable outcome.
4) A poor outcome was present in case of stable disease
(SD), resistant disease (RD), evolving disease (ED),
relapse (RE) or death (MO).
Results
The mean age at SLE diagnosis was 12.8 years (SD = 2.5).
The female/male ratio was 4/1. All children were of
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disease characteristics at the onset of the SLE. The
mean interval from initial symptoms to the SLE diag-
nosis was 23 weeks (SD = 58). Upon exclusion of 3
outlier patients, the interval was reduced to a mean
of 7.8 weeks (SD = 9).
The most frequent initial SLE symptoms were: rash,
fever, edema and arthritis. The group as a whole had a
mean SLEDAI and ECLAM scores of 23.8 (SD = 11.6)
and 6 (SD = 2.3), respectively, and a mean renal SLEDAI
score of 8.2. Thirty-three of the 45 children fulfilled the
criteria for lupus nephritis (LN), of which 29 had a renal
biopsy. ISN Class IV was found in 20 cases and ISN Class
III in 8 cases, one case had complex presentation with
ISN Class III and V simultaneously. Nephritis was more
prevalent in the children < 12 years of age at the time of
the SLE diagnosis. This finding was, however, not statisti-
cally significant (Fisher’s Exact Test p = 0.06). Seventy
percent of the children had a serum complement (C3 or
C4) level below normal. C3 was below normal in 42%
and C4 was below normal in 70% of the LN cases.
Elevated blood pressures were found in 20 of 45
patients primarily in LN patients. Hypertension was
defined as systolic and/or diastolic blood pressure above
the 95th percentile for gender and age. CNS involvement
was found in 6 cases (13%). Serositis was found in 16
(36%) cases. Haemolytic anaemia with a positive
Coombs test was found in 12%. Overall, haematological
abnormalities were found in 81% of the children at pres-
entation. Forty-three patients (96%) had an elevatedTable 1 Demographics and characteristic at disease onset
in 45 Vietnamese children with SLE
Parameter Value
Number of patients 45
Female: male 4:1
Median age at diagnosis 12.1 years
Disease characteristics at diagnosis Present n (%) Absent n
Anti-DNA 43 (95) 2
Nephritis 37 (82) 8
Hematology 35 (78) 10
Malar rash 30 (67) 15
ANA 30 (67) 15
Arthritis 26 (58) 19
Photosensitivity 24 (53) 21
Ulcers 17 (38) 28
Serositis 16 (36) 29
CNS 7 (16) 38
Discoid changes 6 (13) 39
Renal biopsy 30 (67) 15antidsDNA. Mean erythrocyte sedimentation rate (ESR)
was 83.6 (SD = 37.4, normal 0–20 mm/hour).
At a 6-month follow-up of the 33 renal patients, 15
patients were in CR, 5 in PR, 6 had SD, 3 had ED, 2 had
RD, 3 had RE and 4 MO. Seven patients were lost to fol-
low-up. Fifteen had a second renal biopsy after the
course of 6 Cyc treatments. In 13 cases the ISN class
had improved and in 2 cases it remained unchanged. In
the first six months, 4 of the original 45 patients were
know to have died, 2 before initiating treatment (1 with
circulatory collapse and 1 of undiagnosed pneumonia),
and 2 of tuberculosis shortly after initiating Cyc
treatment.
Baseline parameters from the time of the diagnosis were
investigated in order to look for predictors of short-term
disease outcome. A low neutrophil count at the time of
the diagnosis was associated with poor disease outcome
(p = 0.01). The patient age at the time of the diagnosis was
positively correlated to the SLEDAI (p = 0.034) and
ECLAM (p = 0.022), which was attributed to a wider range
of organ involvement in the oldest children (Figure 1).
Discussion
In a prospective study, all new cases of SLE referred to
HCMC Children’s Hospital No. 1 during a 16 months
period were investigated. The ratio female/male of 4/1
was in accordance with the literature. However, a num-
ber of findings differed somewhat from previously pub-
lished reports on childhood-onset SLE. First, the
relatively high mean age of 12.8 years at the time of the
diagnosis was unusual. This finding could be explained
by the fact that no children below the age of 5 years
were included, what could be a true pattern but is more
likely a result of underreporting/lack of diagnosis. An378N =
Age groups cut by 10 y





















Figure 1 Mean and 95% confidence intervals (CI) SLEDAI
scores according to age in 45 Vietnamese children with SLE.
The cut-off is 10 years of age. p = 0.018.
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age at onset had very unspecific symptoms as rash and
fever, making diagnosis more difficult [10]. In Vietnam,
where infectious diseases are one of the major reasons
of morbidity and mortality in young children, the
diagnosis of SLE might prove particularly difficult. The
mean age at diagnosis of childhood-onset SLE has been
described to be different among ethnic groups, and is
reported to be lower among non-Caucasian versus
Caucasians [3,4,11-13].
SLEDAI and ECLAM have been validated as measures
of disease activity for evaluation of response to therapy in
SLE. ECLAM seems to be slightly superior to SLEDAI in
measuring change over time, while SLEDAI seems to be
slightly superior to ECLAM in measuring accumulated
disease activity as a predictor of damage [6-8]. In general,
at the time of referral children often have more severe
disease activity with higher SLEDAI scores than adults
[1,10,14]. The disease patterns for the current study
showed remarkably sick children with a mean SLEDAI of
23.8 and a moderately high SLEDAI renal score. It
remains to be investigated whether SLEDAI and/or
ECLAM exhibit sufficient construct validity, accuracy and
responsiveness in follow-up studies of SLE.
One of the major contributors to the high SLEDAI score
was the 75% proportion of LN cases. This finding was in
accordance with the literature [1,3,10,12,13]. All LN cases
fulfilled criteria of nephritis according to the SLE criteria
and biopsy was done in 89%, the remaining not being sus-
pected of having severe nephritis. As described by others,
class IV was the most dominant feature on biopsy
[1,3,10,11,14-18]. Of all biopsies from nephritis cases, 61%
were classified as ISN class IV and 24% as ISN class III.
No cases of class I - II was found in the initial biopsy,
which could be explained by the fact that biopsies were
done in suspected severe SLE nephritis cases only.
Hypertension was found in 20 of 45. Hypertension at
the time of the diagnosis was not predictive of the short-
term renal outcome. All class IV cases were treated
according to the same protocol including induction
therapy with low-dose Cyc and systemic steroids in 6
consecutive infusions 1 month apart. Follow-up biopsy
(n = 13) after 6 months showed marked improvement in
11 from class IV to III (n = 7) and class II (n = 4), in 2
slightly improvement among class III. Normalization of
the C3 and C4 complements and reduction of protein-
uria by greater than 25% by week 8 has been showed to
strongly predict a good renal response to the SLE treat-
ment [19]. Despite our cohort having a very high renal
SLEDAI score at diagnosis, the majority of the nephritis
patients showed significant improvement at 6 months
followup. The short follow-up did not allow prediction
of renal survival time, although the intensive treatment
might prove predictive of a favourable renal outcome incomparison with results from other studies [11,16-18,20].
As childhood onset SLE is a chronic disease with exposure
to lupus flares over many years, it will be interesting to see
if there is a prognostic benefit to this early response to
therapy in our renal patients in an extended prospective
followup.
The most remarkable haematogical finding was a very
high percentage of Coomb’s positivity (83%) with or
without haemolyctic anaemia. The laboratory technique
used was the slide rather than the tube method. The
technique is well standardized and unlikely to yield false
positive results. An explanation for this phenomenon
could be the high incidence of infections in Vietnamese
children, which in some instances may be followed by a
positive Coombs test.
Central nervous system disease, defined as neurological
involvement plus seizures and psychosis, was found in
13% of cases. Others have described an incidence of CNS
disease from 7.7% to 45%, with infantile SLE having the
highest incidence and a trend of a greater incidence of
CNS involvement in Afro-Americans than in Asian
[10,14,20,21].
Cardio-pulmonary disease was detected in 35% of the
children, which is in accordance with the lupus literature,
except for the Italian group who found a very high inci-
dence in infantile SLE (approximately 75%), and for Gedalia
et al., who found a higher incidence in Afro-Americans
compared to Latin-Americans [10,12,14,20,22].
Malar rash was observed in 66% and discoid lupus in
13%, what was somewhat different from the literature and
may be different among ethnic groups [10,12,14,18,20,22].
Gedalia et al. found a higher frequency of malar rash
and discoid rash among Afro-Americans than Latino-
Americans. Our figures resemble what was found in Afro-
Americans [22].
The very high percentage of positive anti-DNA (95%) is
a well known feature of SLE. Very few investigations of
anti-phospholipid antibodies were done (N = 10), 3 IgM
positive; 8 IgG positive. No coagulation disturbances were
detected. Almost none had investigation of thyroid hor-
mones due to economic reasons.
One patient died prior to treatment in a picture of cir-
culatory collapse shortly after diagnosis without evidence
of a bleeding disorder or intravascular dehydration. This
may have been a case of SLE carditis, though this is
speculative. Jakes et al. found deaths due to cardiovascu-
lar involvement in 6-40% in the Asia-Pacific region [3].
One child died after a severe pneumonitis, with no
microorganism identified, perhaps due to SLE lung involve-
ment. Two patients died of TB. Both were diagnosed with
pulmonary TB after the first infusion of cyclophosphamide
and were on high dose corticosteroids. Chest x-ray before
treatment had been normal. However, no other TB testing
was done.
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lence of SLE in South-East Asia. In the available litera-
ture from the region, the reported incidence rates range
from 0.9 to 3.1 per 100.000 children [3]. The population
in Southern Vietnam below 16 years of age is estimated
to be approximately 10 million. Assuming that all new
childhood SLE patients from South Vietnam were re-
ferred to HCM Children’s Hospital No. 1 during the
study period, a minimum incidence of approximately
0.4/100,000 children might be calculated. However, the
paediatricians at HMC Children’s Hospital most likely
only get to see the top of the iceberg. The true incidence
and prevalence may be considerably higher for several
reasons including under-reporting of the disease, the
diagnostic challenges of SLE, and selection bias.
Conclusions
We report a cohort of 45 newly diagnosed SLE children
from the Southern part of Vietnam. The disease pattern
resembles in many ways the clinical patterns described
by others of childhood onset SLE. However, the cohort
did differ by demonstrating a very severe disease activity
with very high SLEDAI scores and high SLEDAI renal
scores at diagnosis. Although the short time follow-up of
6 months showed favourable histological treatment re-
sponse, the data do not allow prediction of long time pa-
tient and renal survival. We plan an additional follow-up
study that might answer some of these questions.
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